Advanced Clinical
Peptide Therapeutics
A comprehensive post-graduate clinical reference — pharmacology, evidence-based prescribing protocols, condition-specific frameworks, and medico-legal governance. Five structured modules. 62 CME-assessed questions. Five hours of formal credit.
On completion, you will
demonstrate competency in:
Five outcome domains aligned to ACCME criteria for physician continuing education. Each maps directly to a course module and its graded CME assessment component.
Define advanced peptide biochemistry including structural modifications — PEGylation, lipidation, D-amino acid substitution, and cyclisation. Navigate the FDA four-tier regulatory framework across approved, off-label, compounded 503A/503B, and investigational categories. Apply state-level prescribing authority rules for MD, DO, NP, and PA across telemedicine and in-clinic settings, including Ryan Haight Act compliance.
Apply receptor-level pharmacodynamics across GLP-1/GIP, GH-axis, mitochondrial, repair, and immune peptide classes. Interpret PK/PD data to select peptide class by mechanism and patient profile. Implement the mandatory pre-treatment laboratory framework — CMP, CBC, HbA1c, IGF-1, estradiol, ferritin — with threshold-based clinical action criteria for each marker.
Construct peer-referenced prescribing protocols for metabolic, anabolic, repair, and immune peptide classes. Apply evidence-based titration frameworks, monitoring schedules, and stacking interaction rules. Identify absolute and relative contraindications across all five peptide categories and implement the two-failure threshold as a clinical governance standard.
Apply clinical decision frameworks for obesity and metabolic disease, male hypogonadism and fertility, musculoskeletal injury and wound healing, immune dysregulation, sexual medicine, and Long COVID/PEM. Navigate WADA/USADA-prohibited peptides in athlete populations. Use stepwise GLP-1 escalation protocols, GH-axis safety gates, and repair peptide angiogenesis risk stratification.
Implement valid informed consent frameworks distinguishing FDA-approved, off-label, and compounded/investigational disclosure requirements. Execute adverse event reporting via MedWatch. Apply DEA scheduling, state board documentation standards, and compounding pharmacy prescription elements (503A). Classify medico-legal liability tiers and implement risk-stratified practice governance.
62 structured assessment questions distributed across five modules aligned to AMA PRA Category 1 CME criteria. Passing standard of 70% per module and in aggregate for certificate issuance. Distinction (90–100%) and Merit (80–89%) classifications recognise superior performance. Reassessment available after module review.
Five modules.
One clinical framework.
Each module concludes with a graded CME assessment. All content is referenced to peer-reviewed literature, FDA labelling, and clinical evidence current to April 2026.
Built for the
consultation room.
Not a textbook. Not a lecture series. A structured clinical decision framework designed for prescribers who face peptide questions daily — and need answers grounded in regulation, mechanism, and evidence.
Every prescribing scenario is anchored in US federal and state law. FDA tier classifications, DEA scheduling, 503A/503B compounding distinctions, telemedicine prescribing rules under the Ryan Haight Act, and state-by-state NP prescribing authority are addressed directly — with liability implications made explicit throughout.
40+ Harvard-style references embedded throughout each module. Every clinical claim cites peer-reviewed literature or FDA labelling current to April 2026. Social media claims are assessed against the evidence base individually, for every peptide covered. You will know exactly where the evidence ceiling is for each compound.
A mandatory pre-treatment laboratory framework covering CMP, CBC, HbA1c, fasting lipids, IGF-1, testosterone, estradiol, TSH, ferritin, and CK — with specific threshold values that change your clinical decision. Not generic guidance: concrete action thresholds with peptide-specific rationale for every marker in the panel.
62 assessment questions across five modules, aligned to AMA PRA Category 1 CME criteria. Each question maps to a specific course concept. Passing standard of 70% per module and in aggregate. Distinction and Merit classifications for superior performance. Reassessment available after module review.
No brand recommendations. No product purchase links. No compounding pharmacy referrals. No supplement affiliations. The course exists exclusively to advance clinical competency — not to direct prescribers toward any product or commercial arrangement. This is the only peptide education resource that can honestly make this claim.
Stepwise clinical decision trees for the presentations most commonly arising in peptide consultations: obesity and metabolic disease, male hypogonadism, musculoskeletal injury, wound healing, immune dysregulation, sexual medicine, and Long COVID/PEM. Each framework includes peptide selection rationale, contraindication screening, and monitoring protocol.
Everything in
one enrolment.
Advanced education for
licensed practitioners.
This course is designed exclusively for licensed healthcare practitioners operating within their scope of practice under applicable US state and federal law. It is not suitable for patients or unlicensed individuals.
MD / DO
NP
PA
PharmD
Specialists
Medicine Physicians
Specialist
All credentials
CME credit for
demonstrated competency.
Structured to meet ACCME criteria for physician continuing education. Passing standard of 70% per module and in aggregate. CME certificate issued on successful completion.
| Module | Questions | Pass Mark | Min Score | CME Credit |
|---|---|---|---|---|
| Module I — Science & Regulatory | 8 | 6 / 8 | 75% | 0.75 hr |
| Module II — Clinical Pharmacology | 14 | 10 / 14 | 71% | 1.0 hr |
| Module III — Prescribing Protocols | 10 | 7 / 10 | 70% | 1.0 hr |
| Module IV — Condition-Specific Use | 20 | 14 / 20 | 70% | 1.5 hrs |
| Module V — Safety & Medico-Legal | 10 | 7 / 10 | 70% | 0.75 hr |
| Total Course | 62 questions | 44 / 62 | ≥ 70% | 5.0 hrs CME |
Start with
Peptide Fundamentals.
Advanced Clinical Peptide Therapeutics assumes familiarity with core peptide concepts — receptor classes, mechanism categories, dosing principles, stacking rules, and the Fast-Fail safety matrix. Students who have not completed the foundational course may find the advanced clinical content significantly more challenging to apply in practice.
It is strongly recommended that students complete Peptide Fundamentals before enrolling in this advanced course.
- 14 peptides across all five classes — mechanism, dosing, cycling, stacking, and contraindications
- Fast-Fail safety matrix — the two-failure threshold that makes stacking predictably safe or dangerous
- 8 core laboratory markers with specific thresholds and clinical decision criteria
- Social media claims vs actual evidence — assessed for every peptide individually
- WADA/USADA status flagged throughout
- No brand affiliations. No product recommendations. No commercial agenda.
- Semaglutide, Tirzepatide, Retatrutide
- Tesamorelin, hCG, CJC-1295 + Ipamorelin
- SS-31 (Elamipretide), MOTS-C
- BPC-157, TB-500, GHK-Cu
- Thymosin-α1, KPV
- PT-141 (Bremelanotide)
- SLU-PP (metabolic signalling)
- Fast-Fail safety matrix
- Safe-stacking interaction table
- Full contraindications — all 5 classes
- 8 core lab markers with thresholds
- Physician disclosure & consent
Dr Sean Hall
MD · PhD · MBA
Globally experienced healthcare executive, clinician, and strategic advisor. Former Chairman and CEO across public and private healthcare enterprises in the US, Europe, and Australia. International patent holder in advanced therapeutic delivery systems. Published researcher with ORCID: 0000‑0003‑0090‑7895.
Author of Dysevolution (2024). Keynote speaker at Health 2.0 Las Vegas, April 2026 — where the consultation challenge this curriculum addresses was observed firsthand: experienced clinicians confronted by patients who had conducted hundreds of hours of forum research and arrived with specific peptide requests.
Board and government advisor across health systems. This educational program is designed to close the gap between social media peptide discourse and the clinical competency required to respond to it safely and lawfully.
"After my keynote at Health 2.0 Las Vegas, I spent 40 minutes surrounded by experienced clinicians — all confronted by patients who had done 200 hours of forum research and arrived with specific requests."
Most peptide content online is commercially motivated. Most forum advice ignores contraindications. Most prescribers have never seen a Fast-Fail matrix, a stacking interaction table, or a peptide-specific bloodwork protocol. This course delivers exactly that — in rigorous clinical language, built around the questions that arise in the consultation room.
Your advanced clinical
peptide practice starts here.
Hosted securely on Teachable. Lifetime access. CME certificate on completion. No brand affiliations — before, during, or after enrolment.
Students are strongly recommended to complete Peptide Fundamentals before enrolling in this advanced course.
Peptide Therapeutics
- ✓5 clinical modules
- ✓80+ clinical slides
- ✓62 CME assessment questions
- ✓5.0 hours CME credit
- ✓40+ peer-reviewed references
- ✓Lifetime access
- ✓No commercial agenda
This course is designed exclusively for licensed healthcare practitioners operating within their scope of practice under applicable US state and federal law. It is prepared as a continuing medical education (CME) resource and does not constitute clinical advice, replace prescribing guidelines, or supersede FDA labelling. Prescribers remain legally responsible for verifying FDA approval status prior to any prescription, obtaining valid informed consent documenting off-label or investigational status, maintaining contemporaneous medical records per state board requirements, and compliance with DEA scheduling, state pharmacy law, and compounding pharmacy regulations (503A/503B). Content is based on peer-reviewed literature, FDA labelling, and clinical evidence available as of April 2026. Several peptides discussed are not approved by the FDA, TGA, or EMA for human therapeutic use. Some peptides are prohibited under WADA/USADA rules — flagged throughout the course. Clinical decisions require current FDA databases, PubMed, specialist society guidelines, and appropriate specialist oversight. © Dr Sean Hall 2026 · drseanhall.com · All rights reserved · Educational Use Only.